ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2394

18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Abstract Number: 2395

Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group
Abstract Number: 2396

Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis
Abstract Number: 2397

Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis
Abstract Number: 2398

FDG Uptake in Limb Arteries at Diagnosis of Giant Cell Arteritis and Risk of Relapse: An Observational Cohort Study
Abstract Number: 2399

Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis
Abstract Number: 2400

Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept
Abstract Number: 2401

A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis
Abstract Number: 2402

A Retrospective Analysis of Prevalence of Positive Temporal Artery Biopsies in African American Patients with Giant Cell Arteritis (GCA) in a Large Academic Health Center
Abstract Number: 2403

Systole and Diastole Ultrasound Wall Thickness Shows Significant Differences That Affect the Diagnosis and Assessment of Giant Cell Arteritis
Abstract Number: 2404

Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk
Abstract Number: 2405

Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis
Abstract Number: 2406

Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Abstract Number: 2407

Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis
Abstract Number: 2408

The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].